No Prescription |
 |
 | ||
|
Zurig Uloric |
|
| ||
No Prescription » Prescription Drugs 17 » Zurig Uloric Febuxostat is used to treat gout. Gout is a type of arthritis in which uric acid a naturally occurring substance in the body builds up in the joints and causes sudden attacks of redness swelling pain and heat in one or more joints. Febuxostat is in a class of medications called xanthine oxidase inhibitors. It works by decreasing the amount of uric acid that is made in the body. Febuxostat is used to prevent gout attacks but not to treat them once they occur. Buy Zurig Uloric and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Zurig Uloric: Product Type: Prescription Drugs 17 Zurig (Uloric Generic Febuxostat) Zurig (Uloric Generic Febuxostat) Uloric Generic Febuxostat 40mg 70 Tablets 40mg 140(2 x 70) Tablets 40mg 280(4 x 70) Tablets 80mg 70 Tablets 80mg 2 x 70 Tablets 80mg 4 x 70 Tablets Uloric Generic Febuxostat Zurig
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
